$HALO (Halozyme Therapeutics, Inc.)

$HALO {{ '2015-08-10T21:04:08+0000' | timeago}} • Webcast

$HALO 2Q15 Call: Revenues for 2Q15 were $43.4MM compared to $18.4MM for the 2Q14, driven by a $23MM payment for initiation of our agreement with AbbVie. Revenues in 2Q15 included $6.4MM in royalty revenue from sales of products under collaboration agreements, $7.7MM in product sales of bulk rHuPH20 for use in manufacturing collaboration products.

$ALXN {{ '2017-12-07T14:39:46+0000' | timeago}} • Announcement

$ALXN and $HALO announced a collaboration and license agreement that enables $ALXN to use $HALO’s ENHANZE drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. $HALO will receive an initial $40MM with the potential to earn additional payments of up to $160MM for each target developed.

$HALO {{ '2015-12-21T16:11:21+0000' | timeago}} • Announcement

Biotechnology company $HALO said it is partnering with $LLY to develop and commercialize products combining proprietary $LLY compounds with $HALO's ENHANZE platform. $HALO will be paid $25MM initially and will then receive milestone payments of up to $160MM for each of the 5 collaboration targets amounting to $800MM, if milestones are achieved.

$HALO {{ '2015-12-15T21:43:32+0000' | timeago}} • SEC

$HALO granted stock options to purchase approx. 0.8MM and 0.1MM shares of its common stock during 3Q15 and 3Q14, respectively. The exercise price of the stock options granted during 3Q15 and 3Q14 was equal to the closing price of the company's common stock on the date of grant.

$HALO {{ '2015-12-15T21:37:09+0000' | timeago}} • SEC

$HALO's cost of product sales were $6.2MM in 3Q15 compared to $5.1MM in 3Q14. The increase of $1.1MM was due to a $1.2MM increase in bulk rHuPH20 sales to collaboration partners offset by a $0.2MM decrease in Hylenex recombinant cost of product sales. The company's interest expense remained constant at $1.3MM in 3Q15 versus $1.4MM in 3Q14.

$HALO {{ '2015-11-09T22:14:08+0000' | timeago}} • Webcast

At the 3Q15-end, $HALO's cash and cash equivalents and marketable securities were $123.7MM compared to $140.7MM at 3Q14-end. This represents a net cash decrease in the third quarter of 2015 of approx. $17MM from third quarter of 2014.

$HALO {{ '2015-11-09T22:03:22+0000' | timeago}} • Webcast

In 3Q15, $HALO's royalty revenue totaled $8.3MM, which represents an increase of $1.9MM sequentially from last quarter and $5.4MM or nearly 200% from prior-year period. The increase came largely from higher sales of Roche's Herceptin SC during April to June of this year.

$HALO {{ '2015-11-09T21:53:54+0000' | timeago}} • Webcast

During 3Q15, $HALO enrolled more than 100 patients in Stage 2 of Study 202 of investigational new drug PEGPH20 in metastatic pancreatic ductal adenocarcinoma patients. Further, the company plans to complete its target enrollment of 114 patients by the end of 2015 and present results of the study in 2H16.

$HALO {{ '2015-11-09T21:30:11+0000' | timeago}} • Announcement

$HALO's research and development expenses for 3Q15 were $27.6MM, compared to $19.9MM for 3Q14. The planned increase was primarily due to expenses for preclinical and clinical support of PEGPH20.

$HALO {{ '2015-11-09T21:29:13+0000' | timeago}} • Announcement

$HALO's selling, general and administrative expenses for 3Q15 were $10.2MM, compared to $8.6MM for 3Q14. The increase was primarily due to an increase in personnel expenses, including stock compensation, for the period.

$HALO {{ '2015-11-09T21:26:38+0000' | timeago}} • Announcement

For the full year 2015, $HALO maintains its previously announced guidance of: Net revenues to be in the range of $110-115MM; Operating expenses to be in the range of $160-170MM; and Net cash burn to be between $20-30MM.

$HALO {{ '2015-11-09T21:25:36+0000' | timeago}} • Announcement

Biopharmaceutical company $HALO posted a net loss for 3Q15 of $24.5MM or $0.19 per share compared to a net loss in 3Q14 of $20.3MM or $0.16 per share. The company's revenue for the quarter increased 42% YoverY to $20.8MM, driven primarily by an increase in royalties from partner sales of Herceptin SC, MabThera SC and HyQvia.

$HALO {{ '2015-08-24T15:11:46+0000' | timeago}} • Announcement

$HALO Halozyme Therapeutics, Inc. on Aug. 24 named Michael J. LaBarre, as Chief Scientific Officer, succeeding Michael Shepard, who was appointed a Research Fellow.

$HALO {{ '2015-08-10T22:46:43+0000' | timeago}} • Webcast

$HALO 2Q15 Q&A: Yang from Jefferies asked about the primary endpoints of Phase 3 study in pancreatic cancer. Helen replied it will have two primary endpoints; the first one will be PFS and the second one will be overall survival.

$HALO {{ '2015-08-10T22:37:40+0000' | timeago}} • Webcast

$HALO 2Q15 Q&A: Lee from MLV asked are you going through cancer by cancer to look at different cut points or you just looking at pancreatic with Ventana. Helen replied we’ve expended our work with Ventana and started looking also at breast and lung cancer. It is little too early for us to say if cut point will be same between these three tumors.

$HALO {{ '2015-08-10T22:21:56+0000' | timeago}} • Webcast

$HALO 2Q15 Q&A: Duncan from Piper Jaffray asked is the parallel screening standards set up for PRIMAL trial. Helen replied we look forward to giving you an update in November.

$HALO {{ '2015-08-10T22:04:38+0000' | timeago}} • Webcast

$HALO 2Q15 Q&A: Fye of JPMorgan asked about starting PD-1 combo study. Helen replied we articulated as part of our strategy a number of quarters ago that both chemo and immunotherapy are going to play important role in non-small cell lung cancer, so planned & developed separate teams to be driving these programs. So they are not in any way related.

$HALO {{ '2015-08-10T21:44:28+0000' | timeago}} • Webcast

$HALO 2Q15 Q&A: Peters from UBS asked about slower PRIMAL enrollments. Helen replied we’ve identified that it was an element of trial design where we would have a patient in screening and not allow other patients to be screened, due to which we find that we’ve lost a number of patients given some of these patients can be quite ill & progressing.

$HALO {{ '2015-08-10T21:25:17+0000' | timeago}} • Webcast

$HALO 2Q15 Call: We are moving forward with our plans for our Phase 3 study in previously untreated metastatic pancreatic cancer patients following the key end of Phase 2 meeting with FDA and now following scientific advice from EMA. We will complete enrollment of PEGPH20 study 202 by end of 2015.

$HALO {{ '2015-08-10T21:17:11+0000' | timeago}} • Webcast

$HALO 2Q15 Call: Cash, cash equivalents and marketable securities were $140.7MM at June 30, 2015, compared to $128.5MM at March 31, 2015. Net cash increase in 2Q15 was approx. $12.2MM. With the half the year now reported and the addition of the AbbVie agreement, we now expect net revenues to be in the range of $110-115MM for FY15.

$HALO {{ '2015-08-10T21:15:33+0000' | timeago}} • Webcast

$HALO 2Q15 Call: Selling, general and administrative expenses for 2Q15 were $9.8MM, compared to $8.8MM in 2Q14. The increase was primarily due to an increase in personnel expenses, including stock compensation, for the period. Net income for 2Q15 was $3MM or $0.02 per share vs. a net loss of $16.3MM or $0.13 per share in 2Q14.

Recent Transcripts

INFU (InfuSystem Holdings, Inc.)
Friday, November 10 2017 - 4:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, November 8 2017 - 1:30pm
HALO (Halozyme Therapeutics, Inc.)
Tuesday, November 7 2017 - 9:30pm
NVAX (Novavax, Inc.)
Tuesday, November 7 2017 - 9:30pm
INFI (Infinity Pharmaceuticals, Inc.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
PDLI (PDL BioPharma, Inc.)
Thursday, November 2 2017 - 8:30pm
SPPI (Spectrum Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 8:30pm
HSKA (Heska Corporation)
Thursday, November 2 2017 - 3:00pm
NBIX (Neurocrine Biosciences Inc.)
Wednesday, November 1 2017 - 9:00pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
INCY (Incyte Corporation)
Tuesday, October 31 2017 - 2:00pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, October 25 2017 - 8:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm

AlphaGraphics you may like